PP  Vol.5 No.4 , April 2014
Use of Human Embryonic Stem Cell-Derived Cardiomyocyte Clusters to Assess Potential for Chronic Treatment with Compounds to Cause QT Prolongation
ABSTRACT

Drug-induced QT prolongation is a serious clinical issue in developing novel drug candidates and marketing drugs. A major cause of QT prolongation is direct inhibition of human ether-à-go-go-related gene (hERG) channels. Reduction in repolarization-related channel expression levels on plasma membranes is another mechanism that induces QT prolongation. Recently, we established a system for assessing the risk of QT prolongation by using human embryonic stem cell-derived cardiomyocyte clusters (hES-CMCs) in which the field potential duration (FPD) or corrected FPD (FPDc) was measured as an indicator of drug-induced QT interval prolongation. Here, we examined whether this system was able to detect FPDc prolongation caused by pentamidine or probucol, both of which can induce QT prolongation after long-term treatment. hES-CMCs were treated with pentamidine or probucol, and the FPDc of the same clusters was measured 10 min, 4 h, and 24 h after the start of treatment. Concentration-dependent FPDc prolongation was observed at 24 h, but not at 10 min, with pentamidine or probucol treatment. These results suggest that the hES-CMC-based assessment system can be used to detect both acute (at 10 min) and delayed (at 24 h) QT prolongation risk on the same platform by simple alteration of the extended culture period.


Cite this paper
Hihara, T. , Yamazaki, K. , Taniguchi, T. , Yoshinaga, T. , Ito, M. and Sawada, K. (2014) Use of Human Embryonic Stem Cell-Derived Cardiomyocyte Clusters to Assess Potential for Chronic Treatment with Compounds to Cause QT Prolongation. Pharmacology & Pharmacy, 5, 364-371. doi: 10.4236/pp.2014.54044.
References
[1]   Hedley, P.L., Jørgensen, P., Schlamowitz, S., Wangari, R., Moolman-Smook, J., Brink, P.A., Kanters, J.K., Corfield, V.A. and Christiansen, M. (2009) The Genetic Basis of Long QT and Short QT Syndromes: A Mutation Update. Human Mutation, 30, 1486-1511. http://dx.doi.org/10.1002/humu.21106

[2]   Finlayson, K., Turnbull, L., January, C.T., Sharkey, J. and Kelly, J.S. (2001) [3H]Dofetilide Binding to HERG Transfected Membranes: A Potential High Throughput Preclinical Screen. European Journal of Pharmacology, 430, 147-148. http://dx.doi.org/10.1016/S0014-2999(01)01362-0

[3]   Dennis, A., Wang, L., Wan, X. and Ficker, E. (2007) hERG Channel Trafficking: Novel Targets in Drug-Induced Long QT Syndrome. Biochemical Society Transactions, 35, 1060-1063. http://dx.doi.org/10.1042/BST0351060

[4]   Taniguchi, T., Uesugi, M., Arai, T., Yoshinaga, T., Miyamoto, N. and Sawada, K. (2012) Chronic Probucol Treatment Decreases the Slow Component of the Delayed-Rectifier Potassium Current in CHO Cells Transfected with KCNQ1 and KCNE1: A Novel Mechanism of QT Prolongation. Journal of Cardiovascular Pharmacology, 59, 377-386.
http://dx.doi.org/10.1097/FJC.0b013e318245e0c5

[5]   Yamazaki, K., Hihara, T., Taniguchi, T., Kohmura, N., Yoshinaga, T., Ito, M. and Sawada, K. (2012) A Novel Method of Selecting Human Embryonic Stem Cell-Derived Cardiomyocyte Clusters for Assessment of Potential to Influence QT Interval. Toxicology in Vitro, 26, 335-342. http://dx.doi.org/10.1016/j.tiv.2011.12.005

[6]   Goa, K.L. and Campoli-Richards, D.M. (1987) Pentamidine Isethionate. A Review of Its Antiprotozoal Activity, Pharmacokinetic Properties and Therapeutic Use in Pneumocystis carinii Pneumonia. Drugs, 33, 242-258.
http://dx.doi.org/10.2165/00003495-198733030-00002

[7]   Nacher, M., Carme, B., Sainte Marie, D., Couppié, P., Clyti, E., Guibert, P. and Pradinaud, R. (2001) Influence of Clinical Presentation on the Efficacy of a Short Course of Pentamidine in the Treatment of Cutaneous Leishmaniasis in French Guiana. Annals of Tropical Medicine and Parasitology, 95, 331-336.
http://dx.doi.org/10.1080/00034980120064355

[8]   Burchmore, R.J., Ogbunude, P.O., Enanga, B. and Barrett, M.P. (2002) Chemotherapy of Human African Trypanosomiasis. Current Pharmaceutical Design, 8, 256-267. http://dx.doi.org/10.2174/1381612023396159

[9]   Conte, Jr., J.E., Upton, R.A., Phelps, R.T., Wofsy, C.B., Zurlinden, E. and Lin, E.T. (1986) Use of a Specific and Sensitive Assay to Determine Pentamidine Pharmacokinetics in Patients with AIDS. The Journal of Infectious Diseases, 154, 923-929. http://dx.doi.org/10.1093/infdis/154.6.923

[10]   Wharton, J.M., Demopulos, P.A. and Goldschlager, N. (1987) Torsade de Pointes during Administration of Pentamidine Isethionate. The American Journal of Medicine, 83, 571-576. http://dx.doi.org/10.1016/0002-9343(87)90774-1

[11]   Bibler, M.R., Chou, T.C., Toltzis, R.J. and Wade, P.A. (1988) Recurrent Ventricular Tachycardia Due to Pentamidine-Induced Cardiotoxicity. Chest, 94, 1303-1306. http://dx.doi.org/10.1378/chest.94.6.1303

[12]   Girgis, I., Gualberti, J., Langan, L., Malek, S., Mustaciuolo, V., Costantino, T. and McGinn, T.G. (1997) A Prospective Study of the Effect of IV Pentamidine Therapy on Ventricular Arrhythmias and QTc Prolongation in HIV-Infected Patients. Chest, 112, 646-653. http://dx.doi.org/10.1378/chest.112.3.646

[13]   Kroll, C.R. and Gettes, L.S. (2002) T Wave Alternans and Torsades de Pointes after the Use of Intravenous Pentamidine. Journal of Cardiovascular Electrophysiology, 13, 936-938. http://dx.doi.org/10.1046/j.1540-8167.2002.00936.x

[14]   Cortese, L.M., Gasser Jr., R.A., Bjornson, D.C., Dacey, M.J. and Oster, C.N. (1992) Prolonged Recurrence of Pentamidine-Induced Torsades de Pointes. The Annals of Pharmacotherapy, 26, 1365-1369.

[15]   Eisenhauer, M.D., Eliasson, A.H., Taylor, A.J., Coyne Jr., P.E. and Wortham, D.C. (1994) Incidence of Cardiac Arrhythmias during Intravenous Pentamidine Therapy in HIV-Infected Patients. Chest, 105, 389-395.
http://dx.doi.org/10.1378/chest.105.2.389

[16]   Otsuka, M., Kanamori, H., Sasaki, S., Taguchi, J., Harano, H., Ogawa, K., Matsuzaki, M., Mohri, H., Okubo, T., Sumita, S. and Ochiai, H. (1997) Torsades de Pointes Complicating Pentamidine Therapy of Pneumocystis carinii Pneumonia in Acute Myelogenous Leukemia. Internal Medicine (Tokyo), 36, 705-708.
http://dx.doi.org/10.2169/internalmedicine.36.705

[17]   Kuryshev, Y.A., Ficker, E., Wang, L., Hawryluk, P., Dennis, A.T., Wible, B.A., Brown, A.M., Kang, J., Chen, X.-L., Sawamura, K., Reynolds, W. and Rampe, D. (2005) Pentamidine-Induced Long QT Syndrome and Block of hERG Trafficking. The Journal of Pharmacology and Experimental Therapeutics, 312, 316-323.
http://dx.doi.org/10.1124/jpet.104.073692

[18]   Cordes, J.S., Sun, Z., Lloyd, D.B., Bradley, J.A., Opsahl, A.C., Tengowski, M.W., Chen, X. and Zhou, J. (2005) Pentamidine Reduces hERG Expression to Prolong the QT Interval. British Journal of Pharmacology, 145, 15-23.
http://dx.doi.org/10.1038/sj.bjp.0706140

[19]   Yokoyama, H., Nakamura, Y., Iwasaki, H., Nagayama, Y., Hoshiai, K., Mitsumori, Y. and Sugiyama, A. (2009) Effects of Acute Intravenous Administration of Pentamidine, a Typical hERG-Trafficking Inhibitor, on the Cardiac Repolarization Process of Halothane-Anesthetized Dogs. Journal of Pharmacological Sciences, 110, 476-482.
http://dx.doi.org/10.1254/jphs.09071FP

[20]   Yamazaki, K., Hihara, T., Kato, H., Fukushima, T., Fukushima, K., Taniguchi, T., Yoshinaga, T., Miyamoto, N., Ito, M. and Sawada, K. (2014) Beat-to-Beat Variability in Field Potential Duration in Human Embryonic Stem Cell-Derived Cardiomyocyte Clusters for Assessment of Arrhythmogenic Risk, and a Case Study of Its Application. Pharmacology and Pharmacy, 5, 117-128. http://dx.doi.org/10.4236/pp.2014.51017

[21]   Buckley, M.M., Goa, K.L., Price, A.H. and Brogden, R.N. (1989) Probucol. A Reappraisal of Its Pharmacological Properties and Therapeutic Use in Hypercholesterolaemia. Drugs, 37, 761-800.
http://dx.doi.org/10.2165/00003495-198937060-00002

[22]   Jeon, H., Lee, S., Kim, T.-E., Yoon, S.H., Shin, S.-G., Jang, I.-J. and Yu, K.-S. (2011) Pharmacokinetics and Tolerability of Probucol after Multiple Oral Administrations in Healthy Volunteers. International Journal of Clinical Pharmacology and Therapeutics, 49, 688-695. http://dx.doi.org/10.5414/CP201525

[23]   Klein, L. (1981) QT-Interval Prolongation Produced by Probucol. Archives of Internal Medicine, 141, 1102-1103.
http://dx.doi.org/10.1001/archinte.1981.00340080138037

[24]   Matsuhashi, H., Onodera, S., Kawamura, Y., Hasebe, N., Kohmura, C., Yamashita, H. and Tobise, K. (1989) Probucol-Induced QT Prolongation and Torsades de Pointes. Japanese Journal of Medicine, 28, 612-615.
http://dx.doi.org/10.2169/internalmedicine1962.28.612

[25]   Gohn, D.C. and Simmons, T.W. (1992) Polymorphic Ventricular Tachycardia (Torsade de Pointes) Associated with the Use of Probucol. The New England Journal of Medicine, 326, 1435-1436.
http://dx.doi.org/10.1056/NEJM199205213262117

[26]   Tamura, M., Ueki, Y., Ohtsuka, E., Oribe, M., Seita, M., Oribe, K. and Ito, M. (1994) Probucol-Induced QT Prolongation and Syncope. Japanese Circulation Journal, 58, 374-377. http://dx.doi.org/10.1253/jcj.58.374

[27]   Guo, J., Massaeli, H., Li, W., Xu, J., Luo, T., Shaw, J., Kirshenbaum, L.A. and Zhang, S. (2007) Identification of IKr and Its Trafficking Disruption Induced by Probucol in Cultured Neonatal Rat Cardiomyocytes. The Journal of Pharmacology and Experimental Therapeutics, 321, 911-920. http://dx.doi.org/10.1124/jpet.107.120931

[28]   Guo, J., Li, X., Shallow, H., Xu, J., Yang, T., Massaeli, H., Li, W., Sun, T., Pierce, G.N. and Zhang, S. (2011) Involvement of Caveolin in Probucol-Induced Reduction in hERG Plasma-Membrane Expression. Molecular Pharmacology, 79, 806-813. http://dx.doi.org/10.1124/mol.110.069419

[29]   Guo, J., Wang, T., Yang, T., Xu, J., Li, W., Fridman, M.D., Fisher, J.T. and Zhang, S. (2011) Interaction between the Cardiac Rapidly (IKr) and Slowly (IKs) Activating Delayed Rectifier Potassium Channels Revealed by Low K+-Induced hERG Endocytic Degradation. The Journal of Biological Chemistry, 286, 34664-34674.
http://dx.doi.org/10.1074/jbc.M111.253351

 
 
Top